Table of Contents Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Delaware 23-2577138 ...

FORWARD LOOKING STATEMENT ProPhaseLabs.com NASDAQ: PRPH Before we get started, I would like to remind you of the company's Safe Harbor language. During this presentation, we will make forward- looking statements, including statements regarding our strategies, plans, objectives and initiatives and underlying assumptions. While we believe that these forward-looking statements are reasonable as and when made, forward-looking statements are based on expectations that involve risks and uncertainties that could c ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Conference Call March 15, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Hello, and good morning, everyone. Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications. On behalf of our team, we want to thank everyone for joining us today for ProPhase Labs' Fourth Quarter and Ye ...

Exhibit 99.1 ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for rapid revenue and profit growth Completes full transition and right sized operation in Q4 from clinical lab to cutting edge genomics lab Company to hold a conference call Friday ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-21617 Delaware 23-2577138 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2023 Earnings Conference Call November 9, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Yi Chen - H.C. Wainwright Hunter Diamond - Diamond Equity Dennis Waldman - Barrett Productions Operator Good day and welcome the ProPhase Labs Incorporated Third Quarter 2023 Financial Results and Corporate Update. All participants will be in listen-only mode. [Operator Instructions] After today's present ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q2 2023 Earnings Conference Call August 10, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Dennis Waldman - Barrett Productions Yi Chen - H.C. Wainwright Operator Good day, and welcome to the ProPhase Labs Second Quarter 2023 Financial Results and Corporate Update. All participants’ will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2577138 (State or other jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2577138 (State or other jurisdicti ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2023 Results Conference Call May 11, 2023 11:00 AM ET Company Participants Ted Karkus - CEO and Chairman Conference Call Participants Hunter Diamond - Diamond Equity Research Yi Chen - H.C. Wainwright Operator Good day, and welcome to the ProPhase Labs Inc. First Quarter 2023 Financial Results and Corporate Update Conference Call. All participants will be in listen only mode [Operator Instructions]. Please note this event is being recorded. I would now like to turn the ...